Pegfilgrastim Biosimilar Market

Pegfilgrastim Biosimilar Market Analysis and Forecast by Fact.MR

• The global pegfilgrastim biosimilar market covers biosimilar versions of pegfilgrastim used to reduce the incidence of febrile neutropenia in cancer patients receiving myelosuppressive chemotherapy.
• Product formats include prefilled syringes, on-body injectors, and vial presentations delivered through hospital oncology clinics, specialty pharmacies, and ambulatory care centers.
• Growth is shaped by patent expiry of originator pegfilgrastim, expanding oncology patient populations, and increasing payer and institutional preference for biosimilar alternatives that reduce treatment costs while maintaining clinical equivalence.

Summary of Pegfilgrastim Biosimilar Market

• Market Snapshot
  • In 2025, the global Pegfilgrastim Biosimilar Market was valued at approximately USD 4.5 billion.
  • The market is estimated to reach USD 4.84 billion in 2026 and is projected to attain USD 9.97 billion by 2036.
  • The pegfilgrastim biosimilar market is likely to expand at a CAGR of 7.5% during the forecast period.
  • The market is anticipated to create an absolute dollar opportunity of USD 5.13 billion between 2026 and 2036.
  • Subcutaneous Prefilled accounts for 82% of route share in 2026.
  • USA (8.1%) and Mexico (7.7%) are the key growth markets during the forecast period.
• Demand and Growth Drivers
  • Patent expiry of originator pegfilgrastim is enabling broader market entry of biosimilar products across major pharmaceutical markets.
  • Growing oncology patient populations receiving myelosuppressive chemotherapy are expanding the addressable demand for neutropenia prophylaxis.
  • Payer and health system preference for cost-effective biologic alternatives is driving formulary switches from originator to biosimilar pegfilgrastim.
  • Increasing familiarity among oncologists with biosimilar prescribing is reducing physician-level switching resistance.
  • Expansion of biosimilar reimbursement frameworks in emerging markets is creating new demand channels outside established Western markets.
• Product and Segment View
  • Subcutaneous Prefilled accounts for 82% of the route segment in 2026, supported by broad applicability across primary end-use categories.
  • Chemotherapy Induced Neutropenia represents 56% of the application segment in 2026, reflecting sustained institutional demand.
  • Key segmentation includes: Route: Subcutaneous Prefilled, Vials And Others. Setting: Hospital And Oncology Clinics, Specialty Pharmacies, Others. Product: On Body Injector, Standard Prefilled Syringes. Application: Chemotherapy Induced Neutropenia, Hematological Malignancies, Lymphoma, Stem Cell Transplantation.
• Geography and Competitive Outlook
  • North America maintains a leading position supported by established healthcare infrastructure and strong institutional procurement.
  • Europe shows steady demand driven by regulatory frameworks, clinical standards, and aging demographics.
  • Asia Pacific is the fastest-growing region, led by USA (8.1%) and Mexico (7.7%).
  • Key players include Viatris Inc./Biocon Biologics Ltd., Sandoz International GmbH, Coherus BioSciences Inc., Fresenius Kabi AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd..
• Analyst Opinion
  • Shambhu Nath Jha, Principal Consultant at Fact.MR, says 'The pegfilgrastim biosimilar market is past the early adoption phase and entering a volume-driven growth period. Hospital formulary committees are now defaulting to biosimilar pegfilgrastim for new prescriptions, and the competitive landscape is shifting from clinical equivalence debates toward pricing, supply reliability, and on-body injector convenience. Companies that can offer competitive pricing with reliable supply chains and differentiated delivery devices are positioned to capture the largest share of this expanding market.'

Key Growth Drivers, Constraints, and Opportunities

Key Factors Driving Growth

• Rising disease prevalence and aging populations are expanding the addressable patient population requiring specialized products.
• Increasing institutional adoption and clinical guideline integration are supporting procurement growth in hospital and long-term care settings.
• Expanding healthcare infrastructure in developing economies is creating new procurement demand across emerging market facilities.

Key Market Constraints

• Cost sensitivity in price-constrained healthcare settings limits adoption of premium products.
• Limited clinical awareness in certain markets restricts demand growth for specialized products.
• Regulatory differences across countries create compliance complexity for manufacturers.

Key Opportunity Areas

• Development of integrated care kits combining multiple product categories creates higher-value procurement opportunities.
• Expansion of homecare programs opens new demand channels beyond traditional institutional settings.
• Product innovation in safety, monitoring, and ease-of-use features supports premiumization.

Segment-wise Analysis of the Pegfilgrastim Biosimilar Market

• Subcutaneous Prefilled holds 82% of the route segment in 2026.
• Chemotherapy Induced Neutropenia represents 56% of the application segment in 2026.

The pegfilgrastim biosimilar market is segmented by route, setting, product, application, and region.

Which Route Segment Dominates the Pegfilgrastim Biosimilar Market?

Subcutaneous Prefilled is expected to account for approximately 82% of the route segment in 2026. This leadership reflects sustained demand from primary use cases, established procurement patterns, and broad applicability across key end-use categories.

Other segments within this category serve specialized requirements and contribute to overall market diversification. Competition across segments is shaped by product performance, pricing, and alignment with institutional procurement standards.

Which Application Segment Dominates the Pegfilgrastim Biosimilar Market?

Chemotherapy Induced Neutropenia is expected to account for approximately 56% of the application segment in 2026. Demand is shaped by institutional procurement requirements, clinical adoption patterns, and established end-use applications.

Remaining segments serve specific clinical, demographic, or application needs, each contributing to the overall market through differentiated demand drivers and procurement channels.

Which Product Trend is Shaping the Next Phase of Growth in the Pegfilgrastim Biosimilar Market?

On-body injector formats for pegfilgrastim biosimilar delivery are emerging as the fastest-growing product category. Their adoption is projected to rise as oncology clinics and patients shift toward automated wearable devices that deliver the full pegfilgrastim dose approximately 27 hours after application, eliminating the need for a next-day clinic visit. This is particularly relevant for ambulatory oncology settings where reducing patient visit frequency improves treatment adherence and clinic throughput.

The shift toward on-body injectors reflects a broader change in biosimilar competitive dynamics. Manufacturers are moving from price-only differentiation toward device-enabled convenience that improves the patient and provider experience. As a result, on-body injector biosimilars are capturing a growing share of new prescriptions, especially in markets where payers are willing to support device-based delivery formats that reduce hospital resource consumption and improve patient compliance with neutropenia prophylaxis protocols.

Regional Outlook Across Key Markets

• USA leads growth at 8.1%, supported by expanding healthcare infrastructure and rising demand for specialized products.
• Mexico follows at 7.7%, driven by government healthcare programs and increasing clinical adoption.
• Mature markets show steady growth supported by established healthcare systems and replacement demand.

CAGR Table

Source: Fact MR (FMR) analysis, based on proprietary forecasting model and primary research.

Market Outlook for Pegfilgrastim Biosimilar in USA

The USA pegfilgrastim biosimilar market is projected to grow at a CAGR of 8.1% through 2036. Demand is supported by expanding healthcare infrastructure and rising institutional investment.

• Healthcare infrastructure expansion supports procurement growth.
• Clinical adoption rates continue to improve across key facilities.
• Government programs and regulatory frameworks support market development.

Demand Trends in Pegfilgrastim Biosimilar in Mexico

The Mexico pegfilgrastim biosimilar market is projected to grow at a CAGR of 7.7% through 2036. Demand is supported by expanding healthcare infrastructure and rising institutional investment.

• Healthcare infrastructure expansion supports procurement growth.
• Clinical adoption rates continue to improve across key facilities.
• Government programs and regulatory frameworks support market development.

Growth Assessment for Pegfilgrastim Biosimilar in Germany

The Germany pegfilgrastim biosimilar market is projected to grow at a CAGR of 7.3% through 2036. Demand is supported by expanding healthcare infrastructure and rising institutional investment.

• Healthcare infrastructure expansion supports procurement growth.
• Clinical adoption rates continue to improve across key facilities.
• Government programs and regulatory frameworks support market development.

Market Analysis of Pegfilgrastim Biosimilar in France

The France pegfilgrastim biosimilar market is projected to grow at a CAGR of 7.2% through 2036. Demand is supported by expanding healthcare infrastructure and rising institutional investment.

• Healthcare infrastructure expansion supports procurement growth.
• Clinical adoption rates continue to improve across key facilities.
• Government programs and regulatory frameworks support market development.

Opportunity Outlook for Pegfilgrastim Biosimilar in UK

The UK pegfilgrastim biosimilar market is projected to grow at a CAGR of 7% through 2036. Demand is supported by expanding healthcare infrastructure and rising institutional investment.

• Healthcare infrastructure expansion supports procurement growth.
• Clinical adoption rates continue to improve across key facilities.
• Government programs and regulatory frameworks support market development.

Competitive Benchmarking and Company Positioning

Pegfilgrastim Biosimilar Market Analysis By Company

• Viatris Inc./Biocon Biologics Ltd., Sandoz International GmbH, Coherus BioSciences Inc. hold strong positions through broad portfolios and established distribution networks.
• Fresenius Kabi AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd. compete across specific segments, price tiers, and regional markets.
• Competition is shaped by product quality, clinical evidence, pricing, and distribution capabilities.

The competitive landscape is moderately fragmented, with established medical companies competing alongside specialized manufacturers. Product quality, clinical evidence, and service support drive purchasing decisions.

Strategic priorities include expanding product portfolios, strengthening distribution networks, and developing service-linked revenue models.

Key Companies in the Pegfilgrastim Biosimilar Market

Viatris Inc./Biocon Biologics Ltd., Sandoz International GmbH, Coherus BioSciences Inc., Fresenius Kabi AG are among the leading players. Pfizer Inc., Teva Pharmaceutical Industries Ltd., Celltrion Inc., Samsung Bioepis Co. Ltd. hold established positions. Mundipharma International Ltd. compete through focused product offerings.

Recent Industry Developments

• Viatris Inc./Biocon Biologics Ltd. - Product Portfolio Expansion (January 2026)
  • Viatris Inc./Biocon Biologics Ltd. expanded its product portfolio targeting growing demand segments.
• Sandoz International GmbH - Market Expansion (2025)
  • Sandoz International GmbH broadened geographic presence through distribution partnerships.
• Coherus BioSciences Inc. - Technology Enhancement (2025)
  • Coherus BioSciences Inc. introduced technology improvements targeting performance and compliance.

Leading Companies Shaping the Pegfilgrastim Biosimilar Market

• Viatris Inc./Biocon Biologics Ltd.
• Sandoz International GmbH
• Coherus BioSciences Inc.
• Fresenius Kabi AG
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Celltrion Inc.
• Samsung Bioepis Co. Ltd.
• Mundipharma International Ltd.

Sources and Research References

• Viatris Inc./Biocon Biologics Ltd.. Product portfolio and corporate updates.
• Sandoz International GmbH. Product launches and market announcements.
• World Health Organization. Disease prevalence and healthcare infrastructure data.
• Primary interviews with manufacturers, distributors, clinicians, and end users.

This bibliography is provided for reader reference and is not exhaustive. The full report contains the complete reference list and detailed citations.

Key Questions This Report Addresses

• What is the current and future size of the Pegfilgrastim Biosimilar Market?
• How fast is the market expected to grow between 2026 and 2036?
• Which route is likely to lead the market by 2026?
• Which application segment accounts for the highest demand?
• What factors are driving demand globally?
• Which countries show the fastest growth through 2036?
• Who are the key companies in the Pegfilgrastim Biosimilar Market?
• How does Fact.MR estimate and validate the forecast?
• What are the key constraints and opportunities?
• How is product innovation influencing growth?

Pegfilgrastim Biosimilar Market Definition

The pegfilgrastim biosimilar market covers biosimilar versions of pegfilgrastim used for prophylaxis of febrile neutropenia in chemotherapy patients. It includes prefilled syringes, on-body injectors, and vial presentations administered in hospital oncology clinics, outpatient centers, specialty pharmacies, and home care settings.

Pegfilgrastim Biosimilar Market Inclusions

• The scope covers global and regional market size and forecasts for 2026 to 2036 across key segmentation categories and regions.
• It includes regional demand analysis based on disease prevalence, healthcare spending, institutional procurement patterns, and regulatory frameworks.
• The report covers pricing analysis, competitive landscape, and distribution strategies of leading companies.
• It includes technology trends, product innovation, and emerging market dynamics influencing demand growth.

Pegfilgrastim Biosimilar Market Exclusions

• The scope excludes products and services outside the defined market boundary serving different clinical or commercial purposes.
• It excludes non-commercial, custom-built, or research-only systems not available through standard procurement.
• The report excludes informal products with limited quality standardization and market visibility.
• It also excludes adjacent categories that differ in product classification and regulatory pathway.

Pegfilgrastim Biosimilar Market Research Methodology

• The methodology combines secondary research, primary interviews, and forecast modelling.
• It draws on 120+ secondary sources and benchmarks 65+ company product portfolios.
• Market sizing covers 30+ countries through a demand-side model, supported by top-down validation.
• The model cross-checks demand with shipments, pricing trends, channel mix, and product launches.
• Primary validation includes 25+ interviews across manufacturers, distributors, and end users.
• Final estimates go through trade-flow checks, sales-pattern review, and sensitivity testing.